Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice

Pasithea Therapeutics Corp ( (KTTA) ) has provided an update.

On February 20, 2026, Pasithea Therapeutics received a Nasdaq notice that its common stock no longer meets the $1.00 minimum bid price requirement after trading below that threshold for 30 consecutive business days. The notice does not immediately affect the stock’s listing status, and the company’s business operations and SEC reporting obligations remain unchanged.

Pasithea has 180 calendar days, until August 19, 2026, to regain compliance by achieving a closing bid of at least $1.00 for ten straight business days, with the possibility of an additional 180-day period if it meets other listing criteria. If it ultimately fails to cure the deficiency, the stock could face delisting, though the company could appeal, and it is currently monitoring its share price and evaluating options to restore compliance.

The most recent analyst rating on (KTTA) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Pasithea Therapeutics Corp stock, see the KTTA Stock Forecast page.

More about Pasithea Therapeutics Corp

Pasithea Therapeutics Corp. operates in the biopharmaceutical sector, with its common stock listed on The Nasdaq Capital Market. The company’s shares are subject to Nasdaq’s continued listing standards, including minimum bid price and market value requirements that govern its access to public equity markets.

Average Trading Volume: 7,316,063

Technical Sentiment Signal: Sell

Current Market Cap: $16.17M

See more data about KTTA stock on TipRanks’ Stock Analysis page.